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Chronic Administration of the Glucagon-Like Peptide-1
Analog, Liraglutide, Delays the Onset of Diabetes and
Lowers Triglycerides in UCD-T2DM Rats
Bethany P. Cummings,1,2 Kimber L. Stanhope,1,2 James L. Graham,1,2 Denis G. Baskin,3
Steven C. Griffen,4 Cecilia Nilsson,5 Anette Sams,6 Lotte B. Knudsen,5 Kirsten Raun,5 and
Peter J. Havel1,2
OBJECTIVE—The efficacy of liraglutide, a human glucagon-like
peptide-1 (GLP-1) analog, to prevent or delay diabetes in UCD-
T2DM rats, a model of polygenic obese type 2 diabetes, was
investigated.
RESEARCH DESIGN AND METHODS—At 2 months of age,
male rats were divided into three groups: control, food-re-
stricted, and liraglutide. Animals received liraglutide (0.2 mg/kg
s.c.) or vehicle injections twice daily. Restricted rats were food
restricted to equalize body weights to liraglutide-treated rats.
Half of the animals were followed until diabetes onset, whereas
the other half of the animals were killed at 6.5 months of age for
tissue collection.
RESULTS—Before diabetes onset energy intake, body weight,
adiposity, and liver triglyceride content were higher in control
animals compared with restricted and liraglutide-treated rats.
Energy-restricted animals had lower food intake than liraglutide-
treated animals to maintain the same body weights, suggesting
that liraglutide increases energy expenditure. Liraglutide treat-
ment delayed diabetes onset by 4.1  0.8 months compared with
control (P  0.0001) and by 1.3  0.8 months compared with
restricted animals (P  0.05). Up to 6 months of age, energy
restriction and liraglutide treatment lowered fasting plasma
glucose and A1C concentrations compared with control animals.
In contrast, liraglutide-treated animals exhibited lower fasting
plasma insulin, glucagon, and triglycerides compared with both
control and restricted animals. Furthermore, energy-restricted
and liraglutide-treated animals exhibited more normal islet
morphology.
CONCLUSIONS—Liraglutide treatment delays the development
of diabetes in UCD-T2DM rats by reducing energy intake and
body weight, and by improving insulin sensitivity, improving lipid
profiles, and maintaining islet morphology. Diabetes 59:2653–
2661, 2010
Targeting of glucagon-like peptide-1 (GLP-1) forthe pharmaceutical treatment of type 2 diabeteshas shown much promise, as demonstrated bythe clinical success of GLP-1 agonists and dipep-
tidyl peptidase IV (DPP-IV) inhibitors (1,2). As an incretin
hormone, GLP-1 potentiates glucose-induced insulin se-
cretion, avoiding hypoglycemia observed with other phar-
maceutical activators of insulin secretion such as
sulfonylureas (3,4). GLP-1 has also been shown to reduce
excess glucagon secretion, contributing to a reduction in
hyperglycemia (1), and has been suggested to reduce
inflammation (5). GLP-1 signaling increases satiety (6,7)
and slows gastric motility and secretion, further contrib-
uting to a reduction in food intake (8). Furthermore, GLP-1
has been shown to increase -cell differentiation, prolifer-
ation, and insulin synthesis and decrease -cell apoptosis
(9–11). Finally, administration of GLP-1 can improve insu-
lin sensitivity by promoting peripheral glucose uptake and
decreasing hepatic gluconeogenesis, independent of
changes of pancreatic hormone secretion (12–16).
Early attempts to harness these antidiabetic effects
through the production of GLP-1 analogs were complicated
by the short half-life of endogenous GLP-1 (2 min) because
of rapid degradation by the ubiquitously expressed protease,
DPP-IV (17). Thus, one method currently being pursued for
the therapeutic targeting of GLP-1 is production of GLP-1
analogs that are resistant to degradation by DPP-IV. Lira-
glutide is a GLP-1 analog with an additional 16-carbon fatty
acid and a small amino acid–based spacer that confers
reversible binding of the agonist to albumin and increases
resistance to DPP-IV activity, providing liraglutide with a
half-life of approximately 13 h (18,19). These properties allow
once-daily subcutaneous administration of liraglutide for the
treatment of type 2 diabetes.
The efficacy of liraglutide for the treatment of type 2
diabetes has been demonstrated in a number of clinical
studies, with patients showing significant decreases in body
weight, glucose, A1C, and blood pressure (20–25). However,
preclinical studies of the long-term use of chronic liraglutide
administration for the prevention of type 2 diabetes have not
been conducted. With the increasing prevalence of type 2
diabetes, preventive measures are urgently needed. Thus,
this study investigated the metabolic effects of chronic lira-
glutide administration and the potential of liraglutide to
prevent or delay the development of type 2 diabetes in
pre-diabetic UCD-T2DM rats. The UCD-T2DM rat model
develops polygenic adult-onset obesity and insulin resis-
tance, without a monogenic deficit in leptin signaling, fol-
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lowed by inadequate -cell compensation and diabetes in
both male and female animals (26). Thus, the UCD-T2DM rat
more closely models the pathogenesis of type 2 diabetes in
humans than other currently available models. Furthermore,
UCD-T2DM rats demonstrate a later age of diabetes onset
than other rodent models of type 2 diabetes, such as the ZDF
rat, making them highly suitable for diabetes prevention
studies (26,27).
RESEARCH DESIGN AND METHODS
Male UCD-T2DM rats from our colony were individually housed in hanging
wire cages in the Department of Nutrition animal facility at the University of
California, Davis, and maintained on a 1410 h light-dark cycle. Starting when
rats were 2 months of age, male siblings were divided into three groups:
control, food restricted, and liraglutide. Animals with a 2-month body weight
375 g were chosen for the study. Previous data from our laboratory have
shown that animals weighing 375 g at 2 months of age have an average age
of diabetes onset of 113  5 days and a diabetes incidence rate of 98%,
whereas animals weighing 375 g at 2 months of age have an average age of
onset of 219 10 days and a diabetes incidence rate of 89% (26). Body weights
at the time of entry into the study were 398  3, 399  3, and 399  3 g in
control, food-restricted, and liraglutide groups, respectively (n  32 per
group). All animals received ground chow (no. 5012, Ralston Purina, Belmont,
CA) in spill-resistant jars for accurate food intake measurements. Restricted
animals were food restricted to 9% less energy per kg of body weight than was
being consumed by the liraglutide-treated animal in the same cohort to
equalize body weights between these two groups. Food intake and body
weight were measured three times weekly. Control and food-restricted
animals received subcutaneous Dulbecco’s PBS injections (1 ml/kg body
weight) twice daily (0800–1000 h and 1800–2000 h), and liraglutide animals
received subcutaneous liraglutide injections (0.2 mg/kg body weight) twice
daily. Animals received injections after the fasting blood draws and did not
receive an injection on the day of euthanasia. Nonfasting blood glucose was
monitored every week with a glucose meter (LifeScan One-Touch Ultra,
Milpitas, CA) at 1300–1400 h using a lancet to collect a drop of blood from the
tail. Diabetes onset was defined as a nonfasted blood glucose value above 11.1
mmol/l (200 mg/dl) on 2 consecutive weeks. Half of the animals in each group
(n  16) were killed for tissue collection at 6.5 months of age (short-term
study). The remaining half (n  16) continued treatment until the time of
diabetes onset (long-term study). The experimental protocols were approved
by the UC Davis Institutional Animal Care and Use Committee.
Monthly hormone and metabolic profiles. Blood samples were collected
from rats in both the short-term and long-term treatment groups once monthly
after an overnight (13-h) fast and placed into EDTA-treated tubes. The plasma
was separated by centrifugation and assayed for glucose, insulin, glucagon,
triglycerides (TG), cholesterol, and adiponectin. Plasma monocyte chemotac-
tic protein-1 (MCP-1) was measured in plasma samples from 6-month-old rats.
Plasma leptin and intercellular adhesion molecule (I-CAM) were measured in
the final blood sample taken from 6.5-month-old rats from the short-term
group. Twenty-four–hour urine samples were collected from 6-month-old rats
in the short-term groups in sodium azide–treated flasks and assayed for
glucose and albumin.
Plasma glucose, cholesterol, and urine glucose were measured using
enzymatic colorimetric assays for glucose and cholesterol (Thermo DMA
Louisville, CO). Insulin, leptin, glucagon, and adiponectin were measured with
rodent/rat-specific radioimmunoassays (Millipore, St. Charles, MO). TG was
measured with an enzymatic colorimetric assay (L-type TG H kit, Wako
Chemicals, Richmond, VA). Plasma I-CAM was measured when the rats were
6 months of age with an ELISA (R&D, Minneapolis, MN). Plasma monocyte
chemotactic protein-1 (MCP-1) levels were compared in 5 diluted plasma
from 6-month-old rats using the Millipore Milliplex assay (RAT cytokine cat.
no. RCYTO-80K). Urinary albumin excretion was measured using the Albumin
Blue 580 fluorescence assay method described previously (28). A1C was
measured using the direct enzymatic HbA1c kit (Diazyme, Poway, CA).
Body composition and liver and muscle triglyceride content. After 4.5
months of treatment (6.5 months of age), animals in the short-term groups
were killed with an overdose of pentobarbital (200 mg/kg i.p.) after an
overnight fast. Subcutaneous, mesenteric, retroperitoneal, and epididymal
adipose depots and liver, heart, gastrocnemius muscle, and kidney were
dissected, weighed, and flash-frozen in liquid nitrogen and stored at 80°C.
Liver and skeletal muscle TG content were measured using the Folch method
(29) for lipid extraction followed by spectrophotometric measurement of TG
content (Thermo Electron, Louisville, CO). Rats were eviscerated and fat
depots were returned to the carcass for body composition analysis, conducted
as described by Bell and Stern (30). Briefly, carcass weight was determined,
and the carcass was freeze-dried to determine total water weight, placed in a
soxhlet ether extractor to determine total fat weight, and then placed in a
muffle oven to determine total ash weight.
Islet immunohistochemistry and pancreatic insulin content. Pancreas
samples were collected and immunostained, and insulin was extracted and
analyzed as previously described (31).
Statistics and data analysis. Data are presented as mean  SEM. Statistical
analyses were performed using GraphPad Prism 4.00 for Windows, GraphPad
Software, San Diego, CA. Body weight, food intake, and monthly fasting
hormone and metabolite data were compared by two-factor (time and
treatment) repeated-measures ANOVA followed by post hoc analysis with a
Bonferroni multiple comparison test. Incidence data were analyzed by log-
rank testing of Kaplan-Meier survival curves. Age of onset, tissue weights,
tissue TG content, plasma leptin, plasma I-CAM, plasma MCP-1, and body
composition were analyzed by one-factor ANOVA followed by post hoc
analysis with Bonferroni multiple comparison test. Differences were consid-
ered significant at P  0.05. For tissue weights and body composition data,
animals that had become diabetic and had started to lose weight (at least 5%
of peak weight) were not included in this dataset to avoid the confounding
effects of weight loss on tissue TG content and adiposity. Five animals from
the control group and one from the restricted group became diabetic at too
early an age to allow collection of blood samples up to 6 months of age, and
therefore they were included in incidence analysis, but excluded from
longitudinal analyses.
RESULTS
Chronic liraglutide administration delays the onset
of diabetes. Compared with control animals, the onset of
diabetes was delayed in food-restricted and liraglutide-
treated animals by 2.8  0.7 and 4.1  0.8 months of age,
respectively. The mean ages of diabetes onset were 5.2 
0.6, 8.0  0.7, and 9.3  0.8 months in control, food-
restricted, and liraglutide-treated animals, respectively
(Table 1). By 6.5 months of age, only 5 of 32 liraglutide-
TABLE 1
Age of onset and incidence
Control Restricted Liraglutide-treated
Animals treated until 6.5 months of age
Age of onset (days) 127 6 160  6** 163 12*
Incidence (%) 81 38 16
Diabetes-free days 79 7 122 4*** 130  3***
n 32 32 32
Animals treated until onset
Age of onset (days) 156 18 240  22* 280 25**
Incidence (%) 100 100 100
Diabetes-free days† 96 18 179 21* 207 19***
n 16 16 16
Data are mean  SEM unless otherwise indicated. P  0.01 by one-way ANOVA; *P  0.05; **P  0.01; ***P  0.001 compared with control
by Bonferroni post-test. †Diabetes-free days starting at treatment initiation.
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treated animals had become diabetic, whereas 12 of 32
food-restricted and 26 of 32 control animals were diabetic.
Thus, within the first 4 months of treatment, liraglutide
treatment significantly delayed diabetes onset compared
with both the control and food-restricted groups (Fig. 1A).
After 15 months of treatment, liraglutide and food restric-
tion both significantly delayed diabetes onset compared with
control animals (P 0.01), but at this lower sample size and
longer time course of treatment, the time of onset was not
significantly different between food-restricted and liraglutide
long-term treatment groups (Fig. 1B). Nonfasting blood glu-
cose concentrations were significantly elevated in control
animals compared with restricted and liraglutide-treated
animals starting at 4 months of age (Fig. 1C).
Liraglutide treatment reduces energy intake and
body weight. As expected, energy intake and body weight
were significantly higher in control animals compared with
restricted and liraglutide-treated animals throughout the
study (Fig. 2). Energy intake was maintained 9% lower in
restricted animals compared with liraglutide-treated ani-
mals to equalize body weights between these groups.
Control animals began to lose weight at 6 months of age as
the majority of these untreated animals had developed
diabetes and were losing energy because of glucosuria and
polyuria (Table 2). Diabetic animals developed moderate
hyperphagia as previously reported, likely because of
decreases of insulin and leptin (26).
Liraglutide lowers fasting glucose, A1C, insulin, and
urinary albumin excretion. Fasting plasma glucose and
A1C were elevated in control animals compared with
food-restricted and liraglutide-treated animals, reflecting
Control
Restricted
Liraglutide
2 3 4 5 6
100
75
50
25
0
Age (months)
D
ia
be
te
s 
In
ci
de
nc
e 
(%
)
**
**
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
100
75
50
25
0
Age (months)
D
ia
be
te
s 
In
ci
de
nc
e 
(%
)
A
B
2 3 4 5 6
0
5
10
15
20
25
Control
Restricted
Liraglutide
***
***
***
***
Age (months)
N
on
-F
as
tin
g 
B
lo
od
 G
lu
co
se
 (m
m
ol
/l)
C
FIG. 1. Kaplan-Meier analysis of diabetes incidence in control, re-
stricted, and liraglutide-treated animals up to 6 months (n  32 per
group) (A) and 12 months (n 16 per group) (B) of age. ***P< 0.0001,
**P < 0.01 compared with control; *P < 0.05 compared with the
food-restricted group by log-rank test. Nonfasting blood glucose in
control, restricted, and liraglutide-treated animals (C). ***P < 0.0001
by two-factor (time and treatment) repeated-measures ANOVA, ***P<
0.001 compared with restricted and liraglutide-treated animals by
Bonferroni post-test. Control: n  27; restricted: n  31; liraglutide-
treated animals: n  32.
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FIG. 2. Energy intake (A) and body weight (B) in control, restricted,
and liraglutide-treated animals. ***P < 0.0001 by two-factor (time and
treatment) repeated-measures ANOVA; ***P < 0.001 compared with
restricted and liraglutide-treated animals; *P < 0.05 liraglutide-
treated animals versus restricted by Bonferroni post-test. Control: n
27; restricted: n  31; liraglutide-treated animals: n  32.
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the earlier age of onset in this group (Fig. 3A and B).
Similar to urine glucose values, daily urine albumin excre-
tion in 6-month-old rats was significantly higher in control
animals compared with food-restricted and liraglutide-
treated animals (Table 2).
Liraglutide treatment markedly lowered fasted plasma
insulin compared with control and food-restricted animals
starting 1 month into intervention and lasting throughout
the 6-month sampling period, suggesting that the improved
insulin sensitivity was not solely related to reduced body
weight (Fig. 3C) (P  0.001). Fasting insulin concentra-
tions in the control group began to fall starting at 5 months
of age as more of these animals developed diabetes. We
previously reported that fasting plasma insulin concentra-
tions decline progressively with the duration of diabetes in
the UCD-T2DM rat model as a result of -cell failure (26).
Liraglutide decreases body adiposity. In animals killed
at 6.5 months of age, food-restricted and liraglutide-treated
animals weighed significantly less than control animals
and had smaller epididymal and mesenteric adipose de-
pots (Table 3) (P  0.01). Although food restriction
resulted in a decrease of percent body fat content and an
increase of the percent lean body mass compared with
nondiabetic controls, liraglutide treatment further de-
creased percentage body fat and increased lean body mass
compared with food-restricted animals (Table 3). Lira-
glutide-treated animals also had15% lower heart weights
and higher percentage body mineral (bone ash) content
compared with control animals.
Liraglutide lowers fasting TG and liver TG content.
Fasting plasma TG concentrations were reduced50–60%
in liraglutide-treated animals compared with control and
food-restricted animals throughout the 6-month sampling
period (Fig. 4A). Liver TG content was significantly lower
in both food-restricted and liraglutide-treated animals at
6.5 months of age compared with control animals (Table
3). No significant differences in muscle TG content or
plasma cholesterol were observed (Fig. 4B).
Liraglutide lowers plasma glucagon and leptin, main-
tains plasma adiponectin, and does not affect mark-
ers of inflammation. When the rats were 3 months of
age, fasting plasma glucagon concentrations were signifi-
cantly lower in liraglutide-treated animals compared with
food-restricted and control animals (Fig. 4C). Fasting
plasma leptin was significantly lower in liraglutide-treated
animals compared with food-restricted and control ani-
mals at 6.5 months of age, after exclusion of animals that
had become diabetic and had started to lose weight
(control: 1,034  168; restricted: 1,031  344; liraglutide:
730  237 pmol/l; P  0.05; control: n  6; restricted: n 
14; liraglutide: n 14). Plasma adiponectin concentrations
were maintained in restricted and liraglutide animals up to
6 months of age, whereas plasma adiponectin levels fell by
33  12 pmol/l (P  0.05) in 4-month-old rats compared
with baseline concentrations in the control animals (Fig.
4D). Liraglutide treatment did not lower fasting plasma
I-CAM concentrations in 6.5-month-old pre-diabetic ani-
mals compared with control animals; however, food re-
striction significantly lowered I-CAM concentrations
(control: 286.2  54.4; restricted: 202.1  6.1, liraglutide:
355.9  75.1 nmol/l; P  0.05, control compared with
restricted; control: n  6; restricted: n  14; liraglutide:
n  14). Plasma MCP-1 concentrations were lower in
restricted and liraglutide-treated animals compared with
control animals at 6 months of age (control: 3.0  0.5;
restricted: 1.8  0.2; liraglutide: 2.0  0.3 pmol/l; control:
n  29; restricted: n  27; liraglutide: n  29). However,
plasma MCP-1 concentrations were not different between
groups when diabetic animals were excluded (control:
2.2  0.5; restricted: 1.8  0.2; liraglutide: 2.0  0.3 pmol/l;
control: n  11; restricted: n  23; liraglutide: n  27).
Liraglutide and energy restriction improve islet mor-
phology and increase pancreatic insulin content. Im-
munostaining for insulin and glucagon was performed
on a subset of nine animals per group to assess islet
morphology. Figure 5 presents representative images of
islets from control, food-restricted, and liraglutide-
treated animals. Insulin staining appeared greater in
islets from food-restricted and liraglutide-treated ani-
mals compared with control animals. This was expected
since 8 of the 9 control animals had developed diabetes
at the time of kill, whereas only 3 of 9 and 2 of 9 animals
selected for immunostaining were diabetic prior to kill
in the food-restricted and liraglutide-treated groups,
respectively. Animals in the control group had been
diabetic for 64  13 days, whereas animals in the
liraglutide and restricted groups had only been diabetic
for 38  3 and 26  11 days, respectively. There were no
visible differences noted between the islets from the one
nondiabetic control animal and those from the nondia-
betic restricted and liraglutide animals (data not
shown). No significant visible differences in islet mor-
phology were apparent between food-restricted and
liraglutide-treated animals (Fig. 5). Pancreatic insulin
content in the control animals was approximately one-
third of that of food-restricted and liraglutide-treated
animals (Table 3).
DISCUSSION
In the present study, we investigated the favorable meta-
bolic effects of liraglutide administration (0.2 mg/kg body
weight) and the potential of liraglutide to prevent the
development of diabetes in pre-diabetic UCD-T2DM rats.
Previous studies of liraglutide in rodents and humans have
demonstrated reductions of food intake and body weight,
TABLE 2
Urine volume (24-h), urine glucose, and albumin concentrations and excretion in 6-month-old rats
Control Restricted Liraglutide-treated
Urine glucose (mmol/l) 294 40 59  33*** 78 41***
24-h urine volume (ml) 112 19 15  3*** 29 9***
24-h urine glucose output (mg) 7,201 1,473 374 273*** 1,337 823***
Urinary albumin excretion (mg/day) 14.6 4.8 0.6 0.1** 0.9  0.2**
n 16 15 16
Data are means  SEM unless otherwise indicated. P  0.001 by one-way ANOVA; **P  0.01, ***P  0.001 compared with control by
Bonferroni post-test.
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improvements in -cell function, reduced glucagon con-
centrations, and subsequent improvements of insulin sen-
sitivity and plasma glucose (20–25,32,33). In this study, we
report that chronic liraglutide administration substantially
delays the onset of diabetes as assessed by reductions of
circulating glucose and A1C in UCD-T2DM rats compared
with vehicle-treated control animals, and it modestly de-
lays diabetes onset compared with food-restricted animals
matched for body weight.
The large effects of energy restriction alone to delay the
onset of diabetes in this study suggest that a substantial
portion of the effects of chronic liraglutide administration
on diabetes onset are a result of its effect to reduce food
intake and body weight. Reductions of energy intake and
body weight resulting from liraglutide administration are
similar to that reported in other rodent studies (32,33).
Food restriction is well known to lower glucose, A1C, and
requirements for insulin (34); however, long-term compli-
ance with voluntary food restriction regimens is rarely
achieved. Treatment with liraglutide, a long-acting GLP-1
analog, has the benefit of achieving such reductions in
food intake and body weight.
Although energy restriction played a key role in the
effect of liraglutide to delay type 2 diabetes onset, differ-
ences between liraglutide-treated and food-restricted ani-
mals suggest additional antidiabetic actions of liraglutide
treatment. First, similar body weights in the liraglutide and
restricted groups, despite significantly lower food intake
in the restricted group, suggests that liraglutide treatment
increases energy expenditure. This has been previously
suggested by the results of a study in which a 10% increase
of energy expenditure was observed in rats treated with
liraglutide (33). Furthermore, lower percentage of body fat
mass in liraglutide-treated compared with food-restricted
animals, despite similar body weight, is suggestive of a
preferential increase of lipid oxidation with liraglutide
treatment compared with energy restriction alone.
Second, substantially lower fasting plasma insulin con-
centrations in liraglutide-treated animals compared with
food-restricted animals, despite similar plasma glucose
concentrations, suggest that liraglutide administration im-
proves insulin sensitivity, independent of effects on food
intake and body weight. The mechanisms by which GLP-1
signaling improves insulin sensitivity remain incompletely
understood. There is increasing evidence that GLP-1 may act
to enhance peripheral insulin sensitivity and reduce hepatic
gluconeogenesis independent of its effects on pancreatic
hormones (35), which may be mediated by portal GLP-1
receptors that signal to the CNS through vagal afferent nerves
and autonomic efferent signals to insulin target tissues such
as adipose, liver, and muscle (36).
This improvement in insulin sensitivity may have con-
tributed to the lower circulating TG concentrations in
liraglutide-treated compared with both control and food-
restricted animals. Liver TG content was also significantly
lower in liraglutide-treated and food-restricted animals.
Reductions of circulating and ectopic TG content are
likely to contribute to the improvement in insulin sensitiv-
ity, as deposition of TG in the liver impairs insulin signal-
ing through the production of lipid metabolites that reduce
insulin receptor substrate-2 tyrosine phosphorylation (37).
Additional studies are needed to investigate the mecha-
nisms involved in the effects of liraglutide to lower circu-
lating TG and to determine the extent to which this
contributes to the liraglutide-induced improvement of
insulin sensitivity and delay of diabetes onset.
Lower glucagon levels during the first 2 months of
treatment in liraglutide-treated animals may have contrib-
uted to lower glucose levels, as glucagon promotes hepatic
gluconeogenesis and the production of gluconeogenic
substrates from other energy stores (38). This GLP-1–
mediated improvement of 	-cell function is in agreement
with previous studies (1), and it is consistent with in-
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FIG. 3. Fasting circulating glucose (A), A1C (B), and insulin (C) in
control, restricted, and liraglutide-treated animals. ***P < 0.0001 by
two-factor (time and treatment) repeated-measures ANOVA; ***P <
0.001, *P < 0.05 compared with restricted and liraglutide-treated
animals; **P < 0.001 compared with restricted and control; P <
0.001 compared with restricted; P < 0.05 compared with control by
Bonferroni post-test. Control: n  27; restricted: n  31; liraglutide-
treated animals: n  32.
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creased hepatic gluconeogenesis observed in the GLP-1
receptor knockout mouse (39).
The lower plasma leptin concentrations in liraglutide-
treated animals are likely the result of the decreased
insulin levels observed in response to chronic liraglutide
administration, as leptin production is regulated by insu-
TABLE 3
Body composition, tissue TG content, and pancreatic insulin content in 6.5-month-old rats
Control Restricted Liraglutide-treated
Body weight (g) 647 16 574  7*** 573 11***
Epididymal fat depots (g) 12.0 0.4 9.3 0.4** 8.5 0.5***
Retroperitoneal fat depots (g) 13.7 0.3 12.5 0.7 11.1 0.7
Subcutaneous fat depot (g) 61 3 51  3 46  2*
Mesenteric fat depot (g) 11.1 0.5 8.2 0.4** 8.0 0.6**
Total white adipose tissue (g) 98 4 81  5 74  4**
Heart (g) 1.7 0.1 1.5  0.1 1.4  0.1*
Kidney (g) 1.8 0.1 1.7  0.1 1.8  0.1
Liver (g) 21.3 0.9 17.4 0.5*** 17.1 0.4***
Liver TG (mg/g liver) 23.0 1.4 13.3 1.7*** 13.2 1.1**
Skeletal muscle TG (mg/g muscle) 3.3 0.4 4.2  0.6 3.2  0.3
Pancreatic insulin content (
g/g) 7 3 21 3* 25  5**
% Body fat 23.9 0.8 22.6 0.9 20.0 0.9*†
% Lean body mass 21.3 0.1 21.4 0.2 22.1 0.2*†
% Body water 51.2 0.7 52.2 0.8 53.9 0.7
% Body ash 3.6 0.1 3.8  0.1 3.9  0.1**
Data are means  SEM. Control: n  6; restricted: n  14; liraglutide-treated: n  14. For pancreatic insulin content, control: n  10;
restricted: n  9; liraglutide-treated: n  10. One-way ANOVA; *P  0.05; **P  0.01; ***P  0.001 compared with control; †P  0.05
compared with restricted. Data exclude all animals that became diabetic and began losing weight.
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FIG. 4. Fasting plasma TG (A), cholesterol (B), glucagon (C), and adiponectin (D) in control, food-restricted, and liraglutide-treated animals.
***P< 0.0001, *P< 0.05 by two-factor (time and treatment) repeated-measures ANOVA; ***P< 0.001 compared with food-restricted and control;
**P< 0.001 compared with food-restricted; *P< 0.05 compared with control; P< 0.05 compared with food-restricted; P< 0.05 compared with
food-restricted and liraglutide-treated animals by Bonferroni post-test. Control: n  27; restricted: n  31; liraglutide-treated animals: n  32.
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lin-mediated glucose utilization in adipocytes (40). Lower
adiposity in liraglutide-treated rats may also have contrib-
uted to lower leptin concentrations (41). Lower heart
weights in liraglutide-treated animals compared with con-
trol animals appear consistent with the beneficial effects
that GLP-1 signaling has been reported to have on cardiac
function (1). Liraglutide did not have a significant effect on
markers of inflammation in pre-diabetic rats; thus, the
delay in diabetes onset does not appear to be influenced by
inflammatory status.
Several parameters were similar between the food-
restricted and liraglutide-treated groups, further indicating
the importance of energy restriction and reduced adiposity
in delaying the onset of diabetes in the UCD-T2DM rat
model. Circulating levels of the insulin-sensitizing adipo-
cyte hormone adiponectin (41) were elevated in both
liraglutide-treated and food-restricted animals compared
with control animals starting at 4 months of age. This is
reflective of the later age of diabetes onset in these two
treatment groups, as we have previously reported that
adiponectin levels fall after the onset of diabetes in
UCD-T2DM rats, potentially contributing to the progres-
sion of type 2 diabetes (26). Higher circulating adi-
ponectin concentrations may also have contributed to
the lower glucose levels in both the liraglutide-treated
and food-restricted groups by maintaining insulin
sensitivity.
Liraglutide treatment and energy restriction equally
preserved islet morphology and pancreatic insulin con-
tent. Both treatments delayed the onset of diabetes such
that none of the restricted or liraglutide animals had been
diabetic for 1.5 months prior to tissue collection at 6.5
months of age. The deterioration of islet morphology and
insulin staining during the progression of diabetes has
been previously documented in the UCD-T2DM rat model
(26), and it is clearly demonstrated in the control animals
that had diabetes for 1 month. These observations are
also consistent with those reported in pancreata from
humans with type 2 diabetes (42). Thus, the preservation
of islet morphology and pancreatic insulin content during
food restriction or liraglutide administration in UCD-
T2DM rats may be a result of slower weight gain and a
consequent delay in the onset of hyperglycemia and pos-
sibly glucose toxicity. The effects of liraglutide administra-
tion and food restriction to delay the onset of diabetes and
reduce hyperglycemia were also associated with markedly
reduced urinary albumin excretion, indicating that delay-
ing diabetes onset in UCD-T2DM rats delays the develop-
ment of diabetic complications such as nephropathy.
In conclusion, both liraglutide treatment and energy
D
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C
FIG. 5. Representative pancreas sections from control, food-restricted, and liraglutide-treated animals at 6 months of age. Hematoxylin and eosin
staining for control (A), restricted (D), and liraglutide-treated animals (G) is shown. Anti-insulin immunostaining for control (B), restricted (E),
and liraglutide-treated animals (H) is shown. Anti-glucagon immunostaining for control (C), restricted (F), and liraglutide-treated animals (I)
is shown. (A high-quality digital representation of this figure is available in the online issue.)
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restriction delay the onset of type 2 diabetes in UCD-T2DM
rats by slowing weight gain, obesity-associated insulin
resistance, and islet dysfunction. Sustained liraglutide
administration delayed the onset of diabetes compared
with food-restricted, body weight–matched animals. This
delay may be the result of improved insulin sensitivity and
decreased circulating TG and glucagon concentrations
seen with liraglutide administration relative to energy
restriction alone. Thus, chronic liraglutide treatment is an
effective weight management tool that delays the onset of
type 2 diabetes. This is the first preclinical study investi-
gating the long-term use of chronic liraglutide administra-
tion for the prevention of type 2 diabetes. Determining
preventive indications for currently available and develop-
ing therapies is crucial in the attempt to reduce the
growing worldwide burden of type 2 diabetes. Delaying
the onset of type 2 diabetes and reducing hyperglycemia in
predisposed individuals would have multiple benefits, in-
cluding delaying the onset of diabetic complications, im-
proving patient quality of life, and reducing health care
expenses.
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